Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.45 |
| ▸ | CNR1 | P21554 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917201 | 1.00 | CNR2 (0.45) | CNR2CNR1ALDH1A1MAPTKMT2A | |
| SCHEMBL4919417 | 0.88 | SLC6A3 (0.45) | CNR2CNR1KMT2A | |
| SCHEMBL4926309 | 0.88 | SLC6A3 (0.45) | CNR2CNR1KMT2A | |
| SCHEMBL4911239 | 0.84 | CNR2 (0.42) | CNR2CNR1ALDH1A1MAPTKMT2A | |
| SCHEMBL4913225 | 0.81 | CNR2 (0.40) | CNR2CNR1ALDH1A1MAPTKMT2A | |
| SCHEMBL17799011 | 0.78 | CNR2 (0.34) | CNR2CNR1ALDH1A1MAPTKMT2A | |
| SCHEMBL4924815 | 0.74 | SLC6A3 (0.42) | CNR2KMT2A | |
| SCHEMBL2726583 | 0.74 | — | — | |
| SCHEMBL4916637 | 0.73 | GAA (0.39) | CNR2 | |
| SCHEMBL4921780 | 0.73 | GAA (0.39) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | TRPV1, TRPA1, KCNJ2 | CNR2 223/4885CNR1 283/4885ALDH1A1 2307/4885 |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | CNR2 223/4885CNR1 283/4885ALDH1A1 2307/4885 |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MC4R, MC5R, GPR4 | CNR2 82/4885CNR1 74/4885ALDH1A1 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.